Fresh frozen plasma
|This article needs additional citations for verification. (August 2013)|
The phrase fresh frozen plasma (FFP) refers to the liquid portion of human blood that has been frozen and preserved after a blood donation and will be used for blood transfusion. The capitalized phrase Fresh Frozen Plasma in the United States can refer to the fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at −18 °C (−0 °F) or colder within eight hours of collection. The phrase "FFP" is often used to mean any transfused plasma product. The other commonly transfused plasma, PF24, has similar indications as those for FFP with the exception of heat-sensitive proteins in the plasma such as factor V.
The use of plasma and its products has evolved over a period of four decades. The use of FFP has increased tenfold from between the years 2000-2010 and has reached almost 2 million units annually in the United States. This trend may be attributable to multiple factors, possibly including decreased availability of whole blood due to widespread acceptance of the concept of component therapy. FFP contains the labile as well as stable components of the coagulation, fibrinolytic and complement systems; the proteins that maintain oncotic pressure and modulate immunity; and other proteins that have diverse activities. In addition, fats, carbohydrates and minerals are present in concentrations similar to those in circulation. Although well-defined indications exist for the use of FFP in single or multiple coagulation deficiencies, indications for many of its other uses may be empiric.
- 1 Indications
- 2 Risks
- 3 Alternatives
- 4 Effectiveness
- 5 References
- 6 External links
Very few specific indications for the use of FFP exist. These indications generally are limited to the treatment of deficiencies of coagulation proteins for which specific factor concentrates are unavailable or undesirable. In many clinical practices, fresh and frozen plasma contains proteins with two important coagulation factors in it — the V and the VIII. Other documentations indicate FFP has not enough beneficial effect when it's used as a transfusion to stop massive hemorrhage. 
In addition, circumstances exist in which FFP has been employed and is believed to be of therapeutic value, but data supporting its efficacy are limited or unavailable (e.g., multiple coagulation protein deficiencies in the uncontrollably bleeding patient). Because such patients are often critically ill and satisfactory alternative therapy may not be at hand, FFP may be appropriate.
Indications for the use of FFP include the following:
Replacement of isolated factor deficiencies
FFP is efficacious for treatment of deficiencies of factors II, V, VII, IX, X, and XI when specific component therapy is neither available nor appropriate. Requirements for FFP vary with the specific factor being replaced. For example, hemostatic levels of factor IX in a patient with severe deficiency are difficult to achieve with FFP alone, whereas patients with severe factor X deficiency require factor levels of about 10 percent to achieve hemostasis and are easily treated with FFP.
Reversal of warfarin effect
Patients who are anticoagulated with warfarin are deficient in the functional vitamin K dependent coagulation factors II, VII, IX, and X, as well as proteins C and S. These functional deficiencies can be reversed by the administration of vitamin K. However, for anticoagulated patients who are actively bleeding or who require emergency surgery, FFDP (or single-donor plasma) can be used to achieve immediate hemostasis.
Massive blood transfusion (>1 blood volume within several hours)
Use of FFP in massive blood transfusion, for which there is less credible evidence of efficacy, appears to have increased in frequency in the past decade, possibly due in part to the relative unavailability of whole blood. Pathological hemorrhage in the massively transfused patient is caused more frequently by thrombocytopenia than by depletion of coagulation factors. The empiric use of FFP to reverse hemostatic disorders should be confined to those patients in whom factor deficiencies are presumed to be the sole or principal derangement. There is no evidence that the prophylactic administration of FFP decreases transfusion requirements in multiply transfused patients who do not have documented coagulation defects.
It is however exceedingly common for patients to have documented blood clotting abnormalities (Prolonged APTT, INR) after large blood loss requiring for example 4 units or more of packed red blood cells. FFP is commonly recommended in these settings. In urgent situations it may be unacceptable to wait hours for lab test results before blood products are given. Though unlikely to be done, a clinical trial to prove efficacy and lack of adverse effects of giving empiric FFP compared to placebo would not be unethical, since the true risks and benefits of this currently intuitive practice is unknown.
Use in antithrombin III deficiency
Treatment of immunodeficiencies
FFP is useful in infants with secondary immunodeficiency associated with severe protein-losing enteropathy and in whom total parenteral nutrition is ineffectual. FFP also can be used as a source of immunoglobulin for children and adults with humoral immunodeficiency. However, the development of a purified immune globulin for intravenous use largely has replaced Fresh frozen plasma
Treatment of thrombotic thrombocytopenic purpura
FFP may be beneficial for the treatment of thrombotic thrombocytopenic purpura.
The risks of FFP include disease transmission, anaphylactoid reactions, alloimmunization, and excessive intravascular volume, as well as transfusion related acute lung injury (TRALI) and an increase in infections (including surgical wound infections). The potential viral infectivity of FFP probably is similar to that of whole blood and red blood cells. The rate of posttransfusion hepatitis depends on many factors, including donor selection. In rare instances, human immunodeficiency virus (HIV) is transmitted by blood transfusions and possibly by FFP. Allergic or anaphylactoid reactions can occur in response to FFP administration and may vary from hives to fatal noncardiogenic pulmonary edema.
FFP should be blood type-matched to ensure compatibility, as agglutination reactions are possible, though rare. The potential for alloimmunization is present, as demonstrated by the infrequent formation of anti-Rh antibodies. For this reason, plasma containing anti-D antibodies (from an RhD-negative donor) is preferably not given to an RhD-positive recipient, and RhD-positive plasma is avoided in RhD-negative women of child-bearing age. As with any intravenously administered fluid, excessive amounts of FFP may result in hypervolemia and cardiac failure.
Evidence indicates that other plasma components (e.g., single-donor plasma) that do not meet the criteria of FFP may have adequate levels of coagulation factors and are suitable for patients in whom FFP is indicated. Single-donor plasma is efficacious in the treatment of mild deficiencies of stable clotting factors. It also is of value in treatment of multiple deficiencies as in reversal of warfarin effects or in liver disease.
Safe and effective alternative treatment often exists so that FFP is no longer the therapy of choice in many conditions. Cryoprecipitate should be used when fibrinogen or von Willebrand factor is needed. For treatment of hemophilia A, cryoprecipitate or factor VIII concentrates, heated or unheated, are available. For treatment of severe hemophilia B, factor IX complex is preferable. Both of these concentrates are prepared from pooled plasma, and the risk of virus transmission is negligible as there hasn't been an infection since 1985 when techniques were developed to kill off viruses including HIV. The factor IX concentrate carries the additional hazard of thrombogenicity.
Crystalloid, colloid solutions containing human serum albumin or plasma protein fraction, hydroxyethyl starch, and dextran are preferable to FFP for volume replacement. The practice of administering both packed red cells and FFP to the same patient should be discouraged, as this adds to the cost and doubles the infection rate. When conditions are appropriate, whole blood should be given.
The most important alternative to the use of FFP is a comprehensive program of blood conservation. This includes measures such as autologous donation before elective surgery, the infusion of shed blood, and the realization that in many patients normovolemic anemia is not an indication for transfusion.
|This section does not cite any references or sources. (August 2013)|
There is little scientific evidence to support the increasing use of FFP in clinical medicine purely for volume expansion. While FFP is a reliable solution for intravascular volume replacement in acute blood loss, alternative therapies are equally satisfactory and considerably safer. There is no documentation that FFP has a beneficial effect when used as part of the transfusion management of patients with massive hemorrhage. FFP contains the major plasma proteins, including the labile coagulation factors (V and VIII), but in clinical practice other blood components or derivatives usually provide greater efficacy.
Nevertheless, in augmenting replacement of whole blood lost in catastrophic haemorrhage, FFP replacement must be considered along with replacement of packed red blood cells.
- Council of Europe (2007). Guide to the preparation, use and quality assurance of blood components: recommendation no. R (95) 15. Council of Europe. pp. 157–. ISBN 978-92-871-6137-6. Retrieved 16 November 2010.
- Sally V. Rudmann (18 February 2005). Textbook of blood banking and transfusion medicine. Elsevier Health Sciences. pp. 247–. ISBN 978-0-7216-0384-1. Retrieved 16 November 2010.
- "Fresh Frozen Plasma: Is it beneficial?". Retrieved October 3, 2011.
- NIH Consensus Development Program: Fresh Frozen Plasma: Indications and Risks (public domain)
- Circular of Information describing intended uses of transfusion products in the United States